Q-omics provides the consensus-scored UNC93B5 profile across patient tissues and cancer cell-line models. UNC93B5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UNC93B5 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, UNC93B5 RNA expression shows 8,185 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, BRCA, and THYM as cancer lineages where UNC93B5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC93B5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC93B5 survival associations across molecular data types. UNC93B5 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC93B5 RNA expression–survival associations across cancer types. High UNC93B5 expression shows unfavorable associations in UCS, HNSC and COAD, but favorable associations in BLCA, UCEC and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for UNC93B5 RNA expression.
This table summarizes UNC93B5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UNC93B5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC93B5 shows higher tumor expression in BRCA, STAD, COAD, KIRC and BLCA. The BRCA box plot shows higher UNC93B5 RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p = .005).
This table shows molecular features associated with UNC93B5 in patient tissues and cancer cell lines. In patient samples, UNC93B5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
